115 related articles for article (PubMed ID: 28474222)
1. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
Masuda K; Ono A; Aikata H; Kawaoka T; Nelson Hayes C; Teraoka Y; Daijo K; Nakamura-Inagaki Y; Morio K; Fujino H; Kan H; Uchida T; Masaki K; Kobayashi T; Nakahara T; Makokha GN; Zhang Y; Nagaoki Y; Miki D; Tsuge M; Hiramatsu A; Imamura M; Abe-Chayama H; Kawakami Y; Ochi H; Chayama K
J Gastroenterol; 2018 Jan; 53(1):107-118. PubMed ID: 28474222
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method.
Fukubayashi K; Tanaka M; Izumi K; Watanabe T; Fujie S; Kawasaki T; Yoshimaru Y; Tateyama M; Setoyama H; Naoe H; Kikuchi K; Sasaki Y
Cancer Med; 2015 Aug; 4(8):1214-23. PubMed ID: 26044168
[TBL] [Abstract][Full Text] [Related]
3. Association of serum AFP trajectories and hepatocellular carcinoma outcomes after hepatic arterial infusion chemotherapy: A longitudinal, multicenter study.
An C; Wei R; Yao W; Han W; Li W; Shi G; Wu P
Cancer Med; 2024 Jun; 13(11):e7319. PubMed ID: 38819606
[TBL] [Abstract][Full Text] [Related]
4. Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Kong S; Yu H; Wang H; Song J; Yan J
Clin J Gastroenterol; 2023 Dec; 16(6):793-802. PubMed ID: 37740882
[TBL] [Abstract][Full Text] [Related]
5. Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma.
Mizukoshi E; Yamashita T; Arai K; Terashima T; Kitahara M; Nakagawa H; Iida N; Fushimi K; Kaneko S
Cancer Immunol Immunother; 2016 Jun; 65(6):715-25. PubMed ID: 27083166
[TBL] [Abstract][Full Text] [Related]
6. Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma.
Chen CT; Liu TH; Shao YY; Liu KL; Liang PC; Lin ZZ
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884684
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and prognostic model of hepatic arterial infusion chemotherapy for hepatocellular carcinoma with high tumor burden and/or Vp4 tumor thrombus compared with sorafenib: a post-hoc analysis of the FOHAIC-1 trial.
Chen QF; Lyu N; Wang X; Jiang XY; Hu Y; Chen S; Zhong SX; Huang ZL; Chen M; Zhao M
Int J Surg; 2023 Dec; 109(12):3929-3939. PubMed ID: 37678272
[TBL] [Abstract][Full Text] [Related]
8. A multitask deep learning radiomics model for predicting the macrotrabecular-massive subtype and prognosis of hepatocellular carcinoma after hepatic arterial infusion chemotherapy.
He X; Li K; Wei R; Zuo M; Yao W; Zheng Z; He X; Fu Y; Li C; An C; Liu W
Radiol Med; 2023 Dec; 128(12):1508-1520. PubMed ID: 37801197
[TBL] [Abstract][Full Text] [Related]
9. Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review.
Zhu S; Yu Y; Yang M; Liu X; Lai M; Zhong J; Zhao X; Lu L; Liu Y
Expert Rev Anticancer Ther; 2024 Jun; 24(6):423-434. PubMed ID: 38651280
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma.
Xiao Y; Deng W; Luo L; Zhu G; Xie J; Liu Y; Wan R; Wen W; Hu Z; Shan R
BMC Cancer; 2024 May; 24(1):588. PubMed ID: 38745113
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of tumor perfusion on cone-beam CT after hepatic arterial infusion port implantation for evaluating tumor response to hepatic arterial infusion chemotherapy in hepatocellular carcinoma treatment.
Hien PN; Chun HJ; Oh JS; Kim SH; Choi BG
Diagn Interv Radiol; 2023 Nov; 29(6):832-837. PubMed ID: 37695260
[TBL] [Abstract][Full Text] [Related]
12. Vessels encapsulating tumor clusters: a novel efficacy predictor of hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma.
Lin W; Lu L; Zheng R; Yuan S; Li S; Ling Y; Wei W; Guo R
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17231-17239. PubMed ID: 37801135
[TBL] [Abstract][Full Text] [Related]
13. Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.
Öcal O; Schütte K; Kupčinskas J; Morkunas E; Jurkeviciute G; de Toni EN; Ben Khaled N; Berg T; Malfertheiner P; Klümpen HJ; Sengel C; Basu B; Valle JW; Benckert J; Gasbarrini A; Palmer D; Seidensticker R; Wildgruber M; Sangro B; Pech M; Ricke J; Seidensticker M
J Cancer Res Clin Oncol; 2022 Feb; 148(2):475-485. PubMed ID: 33855585
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of sequential sorafenib plus hepatic arterial infusion chemotherapy in patients with Barcelona Clinic Liver Cancer stage B and C hepatocellular carcinoma: a retrospective single-institution study.
Ikuta S; Aihara T; Yamanaka N
Contemp Oncol (Pozn); 2018; 22(3):165-171. PubMed ID: 30455588
[TBL] [Abstract][Full Text] [Related]
15. Advanced hepatocellular carcinoma with major portal vein invasion: Therapeutic outcomes of hepatic arterial infusion chemotherapy vs concurrent radiotherapy.
Chiang CL; Liang HL; Chang KC; Tsai WL; Yu HC; Lin KH; Li MF
J Chin Med Assoc; 2024 Feb; 87(2):171-178. PubMed ID: 38099672
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy.
Kudo M
Liver Cancer; 2012 Sep; 1(2):62-70. PubMed ID: 24159574
[TBL] [Abstract][Full Text] [Related]
17. Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma.
Lim M; Muquith M; Miramontes B; Lee CJ; Espinoza M; Huang YH; Hsiehchen D
Hepatology; 2023 Dec; 78(6):1755-1762. PubMed ID: 37254559
[TBL] [Abstract][Full Text] [Related]
18. Circulating sNinj1 as a novel predictor of prognosis and severity in hepatocellular carcinoma.
Yan L; Su W; Gan D; Li D; Mai L; Wang B; Wang L; Peng L; Jiang L; Wang Z; Hu Q; Chen W
Clin Chim Acta; 2023 Oct; 550():117581. PubMed ID: 37802206
[TBL] [Abstract][Full Text] [Related]
19. First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation.
von Felden J; Schulze K; Gil-Ibanez I; Werner T; Wege H
Diagnostics (Basel); 2016 Nov; 6(4):. PubMed ID: 27916795
[TBL] [Abstract][Full Text] [Related]
20. Increasing evidence for the efficacy of hepatic arterial infusion chemotherapy combined with systemic therapy for advanced hepatocellular carcinoma with macrovascular invasion: time to consider a more effective approach.
Moriya K; Nagamatsu S; Uejima M; Matsuo H
J Gastrointest Oncol; 2023 Oct; 14(5):2282-2286. PubMed ID: 37969841
[No Abstract] [Full Text] [Related]
[Next] [New Search]
